Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR InhibitorsDafne Jacome Sanz, Daniela Ungureanu|Cancers|2021Cited by 31
New insights into the molecular mechanisms of ROR1, ROR2, and PTK7 signaling from the proteomics and pharmacological modulation of ROR1 interactomeJuuli Raivola, Daniela Ungureanu|Cellular and Molecular Life Sciences|2022Cited by 13
Interaction between <scp>ROR</scp> 1 and Mu <scp>SK</scp> activation complex in myogenic cellsHanna Karvonen, Daniela Ungureanu|FEBS Letters|2018Cited by 8
ROR1-PI3K/AKT signaling drives adaptive resistance to cell cycle blockade in TP53 mutated ovarian cancerJuuli Raivola, Daniela Ungureanu|Cell Death and Disease|2026Cited by 1